N-Terminal Pro-Brain Type Natriuretic Peptide Predicts Cardiovascular Events Independently of Arterial Stiffness, Assessed By Carotid-to-Femoral Pulse Wave Velocity, in Apparently Healthy Subjects - 03/04/24
Abstract |
Aim |
This study aimed to evaluate whether N-terminal pro-brain natriuretic peptide (NT-proBNP) and carotid-to-femoral pulse wave velocity (PWV) carried independent prognostic value in predicting cardiovascular events in apparently healthy individuals beyond traditional risk factors.
Methods |
A total of 1,872 participants aged 41, 51, 61, or 71 years from the MONItoring of trends and determinants in CArdiovascular disease (MONICA) study were included. Traditional risk factors were assessed, including: smoking status; mean systolic and diastolic blood pressure; body mass index; fasting plasma glucose; serum triglycerides; total, high-density, and low-density lipoprotein cholesterol; NT-proBNP; and PWV. The principal endpoint that was assessed during 16 years of follow-up was a composite of major adverse cardiovascular events (MACE). The secondary endpoints were cardiovascular mortality (CVM), hospitalisation for coronary artery disease (CAD), and a composite of hospitalisation for heart failure (HF) or atrial fibrillation (AF).
Results |
At baseline, NT-proBNP was associated with PWV (β=0.14; p<0.001), but not after adjustment for traditional risk factors (β=–0.01; p=0.67). In models including traditional risk factors and PWV, NT-proBNP was associated with all four outcomes (HRMACE=1.33, 95% CI 1.16–1.52; HRCVM=2.02, 95% CI 1.65–2.48; HRCAD=1.29, 95% CI 1.07–1.55; and HRHF or AF=1.79, 95% CI 1.40–2.28). In the same model, PWV was only associated with CVM (HRCVM=1.20, 95% CI 1.01–1.41). No interactions between NT-proBNP and PWV were found. N-terminal pro-brain natriuretic peptide significantly improved net reclassification (NRI) for MACE (NRI=0.12; p=0.03), CVM (NRI=0.33; p<0.001), and HF or AF (NRI=0.33; p<0.001) beyond traditional risk factors, while PWV did not aid in net reclassification improvement for any endpoint.
Conclusions |
In apparently healthy individuals, NT-proBNP and PWV predicted cardiovascular events independently. N-terminal pro-brain natriuretic peptide improved reclassification for the prediction of MACE, CVM, and hospitalisation for HF or AF beyond traditional risk factors, while PWV did not.
Le texte complet de cet article est disponible en PDF.Keywords : N-terminal pro-brain type natriuretic peptide, Cardiovascular disease, Risk, Prognosis, Arterial stiffness, Carotid-to-femoral pulse wave velocity
Plan
Vol 33 - N° 3
P. 392-400 - mars 2024 Retour au numéro
Article précédent
- Recovery Rates of Diagnostic Cardiac Procedural Volume in Oceania 1 Year Into COVID-19: The IAEA Non-Invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID 2)
- Anver Sethwala, Cole B. Hirschfeld, Patricia O'Sullivan, Mohamed Akbarally, John Younger, Niels Van Pelt, Michael Randazzo, Dora Lenturut-Katal, Joao V. Vitola, Rodrigo Cerci, Michelle C. Williams, Leslee J. Shaw, Ganesan Karthikeyan, Todd C. Villines, Sharmila Dorbala, Andrew D. Choi, Yosef A. Cohen, Eli Malkovskiy, Thomas N.B. Pascual, Yaroslav Pynda, Maurizio Dondi, Diana Paez, Andrew J. Einstein, Nathan Better, INCAPS COVID Investigators Group
- An Unexpected Diagnosis in a Young Male Presenting With Tricuspid Valve Dysfunction: The Ever-Increasing Key Role of 3D Echocardiogram
- Catarina Amaral Marques, André Cabrita, Carla Sousa, Carlos Xavier Resende, Élson Salgueiro, Cristina Cruz, Rui André Rodrigues
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?